Actively Recruiting
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Led by The Affiliated Hospital of Xuzhou Medical University · Updated on 2025-07-10
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Angioimmunoblastic T cell lymphoma (AITL) is a rare and aggressive lymphoma. Some patients relapsed after initial treatment or did not respond to standard treatment (refractory). Subsequent treatment options are limited and the efficacy is not ideal. This study attempts to explore the possibility of improving the efficacy of immunotherapy combined with chemotherapy and epigenetic regulatory drugs.
CONDITIONS
Official Title
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological diagnosis of angioimmunoblastic T-cell lymphoma (AITL) according to WHO 2016 criteria, with at least one measurable lesion meeting specific size criteria
- Relapsed or refractory disease after at least one systemic therapy including chemotherapy or stem cell transplantation
- Age 18 years or older, any gender, ECOG performance status 0 to 3
- Life expectancy longer than 3 months
- Willingness to understand the disease characteristics and voluntarily participate in treatment and follow-up
You will not qualify if you...
- Abnormal liver or kidney function more than twice the normal values, unless related to lymphoma
- Bone marrow failure with low neutrophil count, platelets, or hemoglobin unless caused by lymphoma infiltration
- Prior use of mitoxantrone or mitoxantrone liposomes, PD-1/PD-L1 inhibitors, or histone deacetylase inhibitors for AITL
- Severe heart failure or significant heart disease within 6 months
- Infection with AIDS, syphilis, active hepatitis B or C
- Other uncontrolled malignancies or hematological disorders
- History of autoimmune disease or recent use of immunosuppressive therapy above certain doses
- Active uncontrolled infections
- Uncontrolled hemophagocytic syndrome
- Recent major surgery within 3 weeks
- Participation in other drug clinical trials within 30 days
- Pregnant or breastfeeding women or unwilling to use contraception
- Known allergies to study drug components
- Investigator judgment deeming patient unsuitable for enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221000
Actively Recruiting
Research Team
W
Wei Sang Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here